Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

NCT03245450 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory or Recurrent Solid Tumors
Rhabdomyosarcoma
Non-Rhabdomyosarcoma Soft Tissue Sarcoma
Ewing Sarcoma

Interventions

DRUG: Eribulin mesilate
DRUG: Irinotecan hydrochloride

Sponsor

Eisai Inc.